p57免疫组化与分子基因分型精细诊断葡萄胎:2217例前瞻性系列更新分析
该研究前瞻性分析2217例潜在葡萄胎标本,联合p57免疫组化与分子基因分型,成功分类2080例(94%),包括571例完全性葡萄胎、498例部分性葡萄胎、900例非葡萄胎及56例雄激素/双亲嵌合体。p57表达与基因分型高度相关,但家族性双亲葡萄胎和供卵妊娠需结合形态学、p57、基因分型及病史综合判断。
要点
- p57免疫组化与基因分型高度相关,是诊断完全性葡萄胎的可靠标志物。
- 完全性葡萄胎多见于<21岁和>45岁患者,后者仅见完全性葡萄胎。
- 家族性双亲葡萄胎和供卵妊娠需结合形态学、p57、基因分型及病史综合判断。
核心结论
- p57免疫组化与基因分型高度相关,可作为完全性葡萄胎的可靠标志物,并识别嵌合体中的葡萄胎成分及雄激素细胞系。
- 家族性双亲葡萄胎和供卵妊娠需结合形态学、p57表达、基因分型数据及病史综合判断,避免误分类。
研究设计与样本
- 前瞻性系列分析2217例潜在葡萄胎标本(2160例子宫,57例异位),来自大型妇科病理实践。
- 联合p57免疫组化与分子基因分型进行分类。
主要发现
- 2080例(94%)成功分类:571例完全性葡萄胎(570例子宫,1例异位),498例部分性葡萄胎(497例子宫,1例异位),900例非葡萄胎(含147例三体、19例双雌三倍体、4例供卵妊娠),56例雄激素/双亲嵌合体;137例复杂或不满意未明确分类。
- 完全性葡萄胎多见于<21岁和>45岁患者,后者仅见完全性葡萄胎。
- 564例成功免疫组化的完全性葡萄胎中563例(99.8%)p57阴性(1例p57阳性[保留母源染色体11]经基因分型为雄激素性)。
- 153例基因分型的完全性葡萄胎中148例(96.7%)为雄激素性(85%单精),5例为双亲性,后者可能为家族性双亲葡萄胎。
- 486例成功免疫组化的部分性葡萄胎中481例(99%)p57阳性(3例p57阴性[母源染色体11缺失],2例机制不明);497例基因分型的部分性葡萄胎中484例(97%)为双雄三倍体(99%双精),13例为三雄四倍体(均至少双精)。
关键数值与推荐
- 完全性葡萄胎p57阴性率99.8%(563/564),基因分型雄激素性率96.7%(148/153),其中单精占85%。
- 部分性葡萄胎p57阳性率99%(481/486),基因分型双雄三倍体率97%(484/497),其中双精占99%。
- 雄激素/双亲嵌合体中37例有p57阴性完全性葡萄胎成分,16例经基因分型证实为雄激素性。
临床怎么用
- 对潜在葡萄胎标本联合应用p57免疫组化与分子基因分型,可提高完全性与部分性葡萄胎及非葡萄胎的鉴别准确性。
- p57阴性可提示完全性葡萄胎,但p57阳性不能完全排除(如保留母源染色体11的雄激素性完全性葡萄胎)。
- 诊断家族性双亲葡萄胎和供卵妊娠需结合形态学、p57表达、基因分型及病史,避免误诊为非葡萄胎或双精完全性葡萄胎。
局限性
- 137例(6%)标本复杂或不满意,未能明确分类。
- 部分病例基因分型或免疫组化未成功,相关比例基于成功检测的病例。
- 家族性双亲葡萄胎和供卵妊娠的识别依赖综合信息,孤立基因分型结果可能导致误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunohistochemical analysis of p57 expression and molecular genotyping accurately subclassify molar specimens into complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM) and distinguish these from nonmolar specimens. Characteristics of a prospective series of potentially molar specimens analyzed in a large gynecologic pathology practice are summarized. Of 2217 cases (2160 uterine, 57 ectopic), 2080 (94%) were successfully classified: 571 CHMs (570 uterine, 1 ectopic), 498 PHMs (497 uterine, 1 ectopic), 900 nonmolar (including 147 trisomies, 19 digynic triploids, and 4 donor egg conceptions), and 56 androgenetic/biparental mosaics; 137 were complex or unsatisfactory and not definitively classified. CHMs dominated in patients aged < 21 and >45 years and were the only kind of molar conception found in the latter group. Of 564 successfully immunostained CHMs, 563 (99.8%) were p57-negative (1 p57-positive [retained maternal chromosome 11] androgenetic by genotyping). Of 153 genotyped CHMs, 148 (96.7%) were androgenetic (85% monospermic) and 5 were biparental, the latter likely familial biparental hydatidiform moles. Of 486 successfully immunostained PHMs, 481 (99%) were p57-positive (3 p57-negative [loss of maternal chromosome 11], 2 unknown mechanism). Of 497 genotyped PHMs, 484 (97%) were diandric triploid (99% dispermic) and 13 were triandric tetraploid (all at least dispermic). Of 56 androgenetic/biparental mosaics, 37 had a p57-negative complete molar component (16 confirmed as androgenetic by genotyping). p57 expression is highly correlated with genotyping, serving as a reliable marker for CHMs, and identifies molar components and androgenetic cell lines in mosaic conceptions. Correlation of morphology, p57 expression, genotyping data, and history are required to recognize familial biparental hydatidiform moles and donor egg conceptions, as the former can be misclassified as nonmolar and the latter can be misclassified as dispermic CHM on the basis of isolated genotyping results.
引用
- Xing D, Adams E, Huang J, et al. Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases. Mod Pathol. 2020. PMID: 33024305. doi:10.1038/s41379-020-00691-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。